Cyclosporin A and the humoral response to blood transfusion in the rat: definition of antigens which suppress alloantibody formation

D.J. Propper, M.C. Jones, Keith Nicol Stewart, G.R.D CATTO, D.A. Power

Research output: Contribution to journalArticle

Abstract

1. Blood transfusions improve renal allograft survival rates, but may induce antibodies which are directed to class I major histocompatibility complex antigens and mediate hyperacute transplant rejection. A model to study the development of such antibodies was developed in inbred strains of rats.

2. The influence of transplantation antigens shared between an initial course of blood transfusions, given with cyclosporin A, and a subsequent antigenic challenge (blood transfusion), given without cyclosporin A, on alloantibody responses to class I major histocompatibility complex antigens was then investigated.

3. Cyclosporin A administration prevented the development of alloantibodies to class I major histocompatibility complex antigens during the initial transfusion period.

4. After the challenge transfusions, alloantibody responses to class I major histocompatibility complex antigens were suppressed when class I major histocompatibility complex or minor histocompatibility antigens were shared between the initial and final transfusions.

5. This suppression only extended to third party class I antigens when minor histocompatibility complex antigens were shared between the initial and final transfusions. Sharing of class I or class II antigens had no effect on alloantibody responses to third party class I antigens coexpressed on the same cell.

6. These studies suggest that cyclosporin A given with blood transfusions may prevent clinical sensitization while permitting the development of suppressor activity, mediated by shared minor histocompatibility complex determinants, to a broad range of potential donor antigens.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalClinical Science
Volume80
Issue number1
Publication statusPublished - Jan 1991

Keywords

  • BLOOD TRANSFUSION
  • CYCLOSPORINE-A
  • SENSITIZATION
  • KIDNEY GRAFT-SURVIVAL
  • ALLOGRAFT SURVIVAL
  • ENHANCEMENT

Cite this

Propper, D. J., Jones, M. C., Stewart, K. N., CATTO, G. R. D., & Power, D. A. (1991). Cyclosporin A and the humoral response to blood transfusion in the rat: definition of antigens which suppress alloantibody formation. Clinical Science, 80(1), 9-15.

Cyclosporin A and the humoral response to blood transfusion in the rat : definition of antigens which suppress alloantibody formation. / Propper, D.J. ; Jones, M.C.; Stewart, Keith Nicol; CATTO, G.R.D ; Power, D.A.

In: Clinical Science, Vol. 80, No. 1, 01.1991, p. 9-15.

Research output: Contribution to journalArticle

Propper, D.J. ; Jones, M.C. ; Stewart, Keith Nicol ; CATTO, G.R.D ; Power, D.A. / Cyclosporin A and the humoral response to blood transfusion in the rat : definition of antigens which suppress alloantibody formation. In: Clinical Science. 1991 ; Vol. 80, No. 1. pp. 9-15.
@article{60729571ee50415d9c79c03d5613cd03,
title = "Cyclosporin A and the humoral response to blood transfusion in the rat: definition of antigens which suppress alloantibody formation",
abstract = "1. Blood transfusions improve renal allograft survival rates, but may induce antibodies which are directed to class I major histocompatibility complex antigens and mediate hyperacute transplant rejection. A model to study the development of such antibodies was developed in inbred strains of rats.2. The influence of transplantation antigens shared between an initial course of blood transfusions, given with cyclosporin A, and a subsequent antigenic challenge (blood transfusion), given without cyclosporin A, on alloantibody responses to class I major histocompatibility complex antigens was then investigated.3. Cyclosporin A administration prevented the development of alloantibodies to class I major histocompatibility complex antigens during the initial transfusion period.4. After the challenge transfusions, alloantibody responses to class I major histocompatibility complex antigens were suppressed when class I major histocompatibility complex or minor histocompatibility antigens were shared between the initial and final transfusions.5. This suppression only extended to third party class I antigens when minor histocompatibility complex antigens were shared between the initial and final transfusions. Sharing of class I or class II antigens had no effect on alloantibody responses to third party class I antigens coexpressed on the same cell.6. These studies suggest that cyclosporin A given with blood transfusions may prevent clinical sensitization while permitting the development of suppressor activity, mediated by shared minor histocompatibility complex determinants, to a broad range of potential donor antigens.",
keywords = "BLOOD TRANSFUSION, CYCLOSPORINE-A, SENSITIZATION, KIDNEY GRAFT-SURVIVAL, ALLOGRAFT SURVIVAL, ENHANCEMENT",
author = "D.J. Propper and M.C. Jones and Stewart, {Keith Nicol} and G.R.D CATTO and D.A. Power",
year = "1991",
month = "1",
language = "English",
volume = "80",
pages = "9--15",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Cyclosporin A and the humoral response to blood transfusion in the rat

T2 - definition of antigens which suppress alloantibody formation

AU - Propper, D.J.

AU - Jones, M.C.

AU - Stewart, Keith Nicol

AU - CATTO, G.R.D

AU - Power, D.A.

PY - 1991/1

Y1 - 1991/1

N2 - 1. Blood transfusions improve renal allograft survival rates, but may induce antibodies which are directed to class I major histocompatibility complex antigens and mediate hyperacute transplant rejection. A model to study the development of such antibodies was developed in inbred strains of rats.2. The influence of transplantation antigens shared between an initial course of blood transfusions, given with cyclosporin A, and a subsequent antigenic challenge (blood transfusion), given without cyclosporin A, on alloantibody responses to class I major histocompatibility complex antigens was then investigated.3. Cyclosporin A administration prevented the development of alloantibodies to class I major histocompatibility complex antigens during the initial transfusion period.4. After the challenge transfusions, alloantibody responses to class I major histocompatibility complex antigens were suppressed when class I major histocompatibility complex or minor histocompatibility antigens were shared between the initial and final transfusions.5. This suppression only extended to third party class I antigens when minor histocompatibility complex antigens were shared between the initial and final transfusions. Sharing of class I or class II antigens had no effect on alloantibody responses to third party class I antigens coexpressed on the same cell.6. These studies suggest that cyclosporin A given with blood transfusions may prevent clinical sensitization while permitting the development of suppressor activity, mediated by shared minor histocompatibility complex determinants, to a broad range of potential donor antigens.

AB - 1. Blood transfusions improve renal allograft survival rates, but may induce antibodies which are directed to class I major histocompatibility complex antigens and mediate hyperacute transplant rejection. A model to study the development of such antibodies was developed in inbred strains of rats.2. The influence of transplantation antigens shared between an initial course of blood transfusions, given with cyclosporin A, and a subsequent antigenic challenge (blood transfusion), given without cyclosporin A, on alloantibody responses to class I major histocompatibility complex antigens was then investigated.3. Cyclosporin A administration prevented the development of alloantibodies to class I major histocompatibility complex antigens during the initial transfusion period.4. After the challenge transfusions, alloantibody responses to class I major histocompatibility complex antigens were suppressed when class I major histocompatibility complex or minor histocompatibility antigens were shared between the initial and final transfusions.5. This suppression only extended to third party class I antigens when minor histocompatibility complex antigens were shared between the initial and final transfusions. Sharing of class I or class II antigens had no effect on alloantibody responses to third party class I antigens coexpressed on the same cell.6. These studies suggest that cyclosporin A given with blood transfusions may prevent clinical sensitization while permitting the development of suppressor activity, mediated by shared minor histocompatibility complex determinants, to a broad range of potential donor antigens.

KW - BLOOD TRANSFUSION

KW - CYCLOSPORINE-A

KW - SENSITIZATION

KW - KIDNEY GRAFT-SURVIVAL

KW - ALLOGRAFT SURVIVAL

KW - ENHANCEMENT

M3 - Article

VL - 80

SP - 9

EP - 15

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 1

ER -